Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bomgaars, L.
Right arrow Articles by Blaney, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bomgaars, L.
Right arrow Articles by Blaney, S. M.
The Oncologist, Vol. 6, No. 6, 506-516, December 2001
© 2001 AlphaMed Press

The Development of Camptothecin Analogs in Childhood Cancers

Lisa Bomgaars, Stacey L. Berg, Susan M. Blaney

Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA

Correspondence: Lisa Bomgaars, M.D., 6621 Fannin Street, MC 3-3320, Houston, Texas 77030-2399, USA. Telephone: 832-824-4588; Fax: 832-825-4039; e-mail: lbomgaars{at}txccc.org

Camptothecin analogs, agents that target the intranuclear enzyme topoisomerase I, represent a promising new class of anticancer drugs for the treatment of childhood cancer. In preclinical studies, camptothecins, such as topotecan and irinotecan, are highly active against a variety of pediatric malignancies including neuroblastomas, rhabdomyosarcomas, gliomas, and medulloblastomas. In this paper, we review the status of completed and ongoing clinical trials and pharmacokinetic studies of camptothecin analogs in children. These and future planned studies of this novel class of cytotoxic agents are critical to defining the ultimate role of topoisomerase I poisons in the treatment of childhood cancer.

Key Words. Topoisomerase I • Topotecan • Irinotecan • SN-38 • 9-aminocamptothecin • Camptothecin • Pediatrics




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
M. Puppo, F. Battaglia, C. Ottaviano, S. Delfino, D. Ribatti, L. Varesio, and M. C. Bosco
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1{alpha} and -2{alpha}
Mol. Cancer Ther., July 1, 2008; 7(7): 1974 - 1984.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Panetta, P. Schaiquevich, V. M. Santana, and C. F. Stewart
Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma
Clin. Cancer Res., January 1, 2008; 14(1): 318 - 325.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Metzger, C. F. Stewart, B. B. Freeman III, C. A. Billups, F. A. Hoffer, J. Wu, M. J. Coppes, R. Grant, M. Chintagumpala, E. A. Mullen, et al.
Topotecan Is Active Against Wilms' Tumor: Results of a Multi-Institutional Phase II Study
J. Clin. Oncol., July 20, 2007; 25(21): 3130 - 3136.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. F. Stewart, J. C. Panetta, M. A. O'Shaughnessy, S. L. Throm, C. H. Fraga, T. Owens, T. Liu, C. Billups, C. Rodriguez-Galindo, A. Gajjar, et al.
UGT1A1 Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose Irinotecan
J. Clin. Oncol., June 20, 2007; 25(18): 2594 - 2600.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Vassal, D. Couanet, E. Stockdale, A. Geoffray, B. Geoerger, D. Orbach, F. Pichon, J. C. Gentet, S. Picton, C. Bergeron, et al.
Phase II Trial of Irinotecan in Children With Relapsed or Refractory Rhabdomyosarcoma: A Joint Study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group
J. Clin. Oncol., February 1, 2007; 25(4): 356 - 361.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncologyHome page
J. Mora, O. Cruz, S. Gala, and R. Navarro
Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin
Neuro Oncology, January 1, 2007; 9(1): 39 - 46.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M.-G. Song, S.-M. Gao, K.-M. Du, M. Xu, Y. Yu, Y.-H. Zhou, Q. Wang, Z. Chen, Y.-S. Zhu, and G.-Q. Chen
Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase C{delta}-dependent mechanisms
Blood, May 1, 2005; 105(9): 3714 - 3721.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Smith and B. D. Anderson
A Window on Reality?
J. Clin. Oncol., April 15, 2004; 22(8): 1360 - 1362.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2001 by AlphaMed Press.
Advertisement